NASDAQ: AKTS
Aktis Oncology Inc Earnings Dates, Reports, Calls

Aktis Oncology earnings were -$63.7M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest AKTS earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$15.1M, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AKTS reported annual earnings of -$63.7M, with 44.9% growth.

AKTS earnings history

Current Revenue
$6.5M
Current Earnings
-$63.7M
Current Profit Margin
-980.9%

AKTS Return on Equity

Insufficient data to display

AKTS Return on Assets

Current Company
-21.6%
Current Industry
-9.6%
AKTS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AKTS announces earnings.

AKTS Return on Capital Employed

Current Company
-27.28%
Current Industry
-3.7%

AKTS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AKTS-$61.40M-$63.73MN/A-$78.34
JANX-$111.60M-$113.63MN/A-$1.83
XNCR-$46.98M-$91.92MN/A-$1.24
EVMN-$67.48M-$68.87MN/A-$11.22
JBIO-$127.24M-$127.41MN/A-$3.19

Aktis Oncology Earnings Reports & History FAQ

What were Aktis Oncology's earnings last quarter?

Aktis Oncology (NASDAQ: AKTS) reported Q4 2025 earnings per share (EPS) of -$18.17, up 12.86% year over year. Total AKTS earnings for the quarter were -$15.14 million. In the same quarter last year, Aktis Oncology's earnings per share (EPS) was -$16.10.

If you're new to stock investing, here's how to buy Aktis Oncology stock.

Is Aktis Oncology profitable or losing money?

As of the last Aktis Oncology earnings report, Aktis Oncology is currently losing money. Aktis Oncology's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$63.73 million, a 44.91% increase year over year.

What was AKTS's earnings growth in the past year?

As of Aktis Oncology's earnings date in Q2 2026, Aktis Oncology's earnings has grown year over year. AKTS earnings in the past year totalled -$63.73 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.